# MXD4

## Overview
MXD4 is a gene that encodes the MAX dimerization protein 4, a member of the MAD family of transcriptional repressors. This protein is characterized by its basic helix-loop-helix (bHLH) domain, which facilitates dimerization with the MAX protein, allowing it to bind to E-box sequences in DNA and repress transcription. As a transcriptional repressor, MAX dimerization protein 4 plays a significant role in regulating gene expression, particularly by antagonizing MYC-mediated transcriptional activation. This function is crucial for controlling cell proliferation, differentiation, and apoptosis, thereby contributing to cellular homeostasis and acting as a tumor suppressor. Alterations in MXD4 expression have been implicated in various cancers, including acute myeloid leukemia, where its repression is linked to the activation of oncogenic pathways (Hu2022Targeting; ConacciSorrell2014An; Prochownik2022Normal).

## Structure
MXD4 (MAX dimerization protein 4) is a member of the MAD family of transcriptional repressors, characterized by its interaction with the MAX protein to regulate gene expression. The primary structure of MXD4 consists of a sequence of amino acids that form the protein, including a basic helix-loop-helix (bHLH) domain, which is crucial for DNA binding and dimerization (ConacciSorrell2014An). This domain facilitates the formation of heterodimers with MAX, allowing MXD4 to bind to E-box sequences and repress transcription (ConacciSorrell2014An).

The secondary structure of MXD4 includes alpha helices and beta sheets, which contribute to its overall stability and function. The tertiary structure involves the three-dimensional folding of the protein, enabling it to interact effectively with MAX. In terms of quaternary structure, MXD4 forms heterodimers with MAX, which is essential for its role in transcriptional repression (ConacciSorrell2014An).

Post-translational modifications, such as phosphorylation, may occur, affecting MXD4's activity and stability. These modifications can influence the protein's function and interactions. Additionally, splice variant isoforms of MXD4 may exist, potentially resulting in different functional properties, although specific details on these variants are not provided in the context.

## Function
MXD4 (MAX dimerization protein 4) is a transcriptional repressor that plays a crucial role in regulating gene expression by forming heterodimers with the MAX protein. This interaction allows MXD4 to compete with MYC for binding to E-box elements in target genes, thereby inhibiting MYC-mediated transcriptional activation (ConacciSorrell2014An; Prochownik2022Normal). MXD4 is involved in controlling cell proliferation, differentiation, and apoptosis, contributing to cellular homeostasis (Prochownik2022Normal).

In healthy human cells, MXD4 is primarily active in the nucleus, where it influences various cellular processes by modulating the expression of target genes. It acts as a tumor suppressor and an inhibitor of proliferation, particularly during cell differentiation. For instance, in murine erythroleukemia cells, MXD4 is induced during terminal differentiation, leading to proliferative quiescence and erythroid lineage commitment (Prochownik2022Normal). MXD4 expression is associated with cell cycle arrest, as it reduces cyclin-dependent kinases 4 and 6 and increases the Cdk inhibitor p27 kip1, which are targets of MYC (Prochownik2022Normal). This regulatory function highlights MXD4's role in maintaining cellular balance and preventing uncontrolled cell growth.

## Clinical Significance
Alterations in the expression of the MXD4 gene have been implicated in various cancers, particularly acute myeloid leukemia (AML). In AML, MXD4 acts as a MYC antagonist, and its repression by UHRF1 is linked to the activation of MYC signaling pathways, promoting leukemic cell self-renewal. The interaction between UHRF1 and SAP30 is crucial for the repression of MXD4, and disrupting this interaction can lead to increased MXD4 expression, which suppresses leukemogenesis (Hu2022Targeting). 

In the context of Flt3-ITD-induced myeloproliferative disease, a condition associated with AML, the expression of MXD4 is decreased, contributing to the proliferation of leukemic cells. Targeting the Myc network, including MXD4, is considered a potential therapeutic strategy for treating Flt3-ITD mutated AML (Basit2018The).

Additionally, a novel MXD4-NUTM1 fusion transcript has been identified in primary ovarian undifferentiated small round cell sarcoma, suggesting its potential role as an oncogenic driver in this rare tumor type (Tamura2018Novel). The MXD4 gene's role as a tumor suppressor is further supported by its involvement in cell differentiation and proliferation, with high expression levels associated with favorable survival in some cancers (Prochownik2022Normal).

## Interactions
MXD4 (MAX dimerization protein 4) is known to interact with the MAX protein to form a heterodimer, which binds to E-box sequences in DNA, thereby repressing transcription. This interaction is crucial for regulating cell proliferation and differentiation by antagonizing MYC-mediated transcriptional activation. In the context of acute myeloid leukemia (AML), MXD4 is repressed by UHRF1 through methylation of its promoter, which is essential for leukemogenesis. The repression of MXD4 activates the MYC signaling pathway, promoting the self-renewal of leukemia-initiating cells (LICs) (Hu2022Targeting).

The interaction between UHRF1 and SAP30, a component of the histone deacetylase complex, is critical for the repression of MXD4. SAP30 binds to UHRF1, allowing it to colocalize at the regulatory regions of the MXD4 gene, leading to its methylation (Hu2022Targeting). This methylation is necessary for the activation of MYC target genes such as E2F1, contributing to leukemogenesis (Hu2022Targeting).

In T cells, MXD4 is stabilized following OX40 engagement, which leads to increased cell survival. This stabilization is important for counteracting c-Myc-induced apoptosis, suggesting a protective role for MXD4 in T-cell survival (Vasilevsky2011OX40).


## References


[1. (Basit2018The) Farhan Basit, Maria Andersson, and Anne Hultquist. The myc/max/mxd network is a target of mutated flt3 signaling in hematopoietic stem cells in flt3-itd-induced myeloproliferative disease. Stem Cells International, 2018:1–9, October 2018. URL: http://dx.doi.org/10.1155/2018/3286949, doi:10.1155/2018/3286949. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1155/2018/3286949)

[2. (Vasilevsky2011OX40) Nicole A. Vasilevsky, Carl E. Ruby, Peter J. Hurlin, and Andrew D. Weinberg. Ox40 engagement stabilizes mxd4 and mnt protein levels in antigen‐stimulated t cells leading to an increase in cell survival. European Journal of Immunology, 41(4):1024–1034, March 2011. URL: http://dx.doi.org/10.1002/eji.201040449, doi:10.1002/eji.201040449. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/eji.201040449)

[3. (ConacciSorrell2014An) M. Conacci-Sorrell, L. McFerrin, and R. N. Eisenman. An overview of myc and its interactome. Cold Spring Harbor Perspectives in Medicine, 4(1):a014357–a014357, January 2014. URL: http://dx.doi.org/10.1101/cshperspect.a014357, doi:10.1101/cshperspect.a014357. This article has 308 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a014357)

[4. (Prochownik2022Normal) Edward V. Prochownik and Huabo Wang. Normal and neoplastic growth suppression by the extended myc network. Cells, 11(4):747, February 2022. URL: http://dx.doi.org/10.3390/cells11040747, doi:10.3390/cells11040747. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11040747)

[5. (Hu2022Targeting) Cheng-Long Hu, Bing-Yi Chen, Zijuan Li, Tianbiao Yang, Chun-Hui Xu, Ruirui Yang, Peng-Cheng Yu, Jingyao Zhao, Ting Liu, Na Liu, Bin Shan, Qunling Zhang, Junhong Song, Ming-Yue Fei, Li-Juan Zong, Jia-Ying Zhang, Ji-Chuan Wu, Shu-Bei Chen, Yong Wang, Binhe Chang, Dan Hou, Ping Liu, Yilun Jiang, Xiya Li, Xinchi Chen, Chu-Han Deng, Yi-Yi Ren, Roujia Wang, Jiacheng Jin, Kai Xue, Ying Zhang, Meirong Du, Jun Shi, Ling-Yun Wu, Chun-Kang Chang, Shuhong Shen, Zhu Chen, Sai-Juan Chen, Xiaolong Liu, Xiao-Jian Sun, Mingyue Zheng, and Lan Wang. Targeting uhrf1-sap30-mxd4 axis for leukemia initiating cell eradication in myeloid leukemia. Cell Research, 32(12):1105–1123, October 2022. URL: http://dx.doi.org/10.1038/s41422-022-00735-6, doi:10.1038/s41422-022-00735-6. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41422-022-00735-6)

[6. (Tamura2018Novel) Ryo Tamura, Hirofumi Nakaoka, Kosuke Yoshihara, Yutaro Mori, Nozomi Yachida, Nobumichi Nishikawa, Teiichi Motoyama, Shujiro Okuda, Ituro Inoue, and Takayuki Enomoto. Novel mxd4–nutm1 fusion transcript identified in primary ovarian undifferentiated small round cell sarcoma. Genes, Chromosomes and Cancer, 57(11):557–563, October 2018. URL: http://dx.doi.org/10.1002/gcc.22668, doi:10.1002/gcc.22668. This article has 29 citations.](https://doi.org/10.1002/gcc.22668)